HUMAN S100B ELISA
Product Data Sheet
Cat. No.: RD192090100R
For Research Use Only
Page 1 of 24 ENG.006.A
CONTENTS
1. INTENDED USE 3 2. STORAGE, EXPIRATION 3 3. INTRODUCTION 4 4. TEST PRINCIPLE 4 5. PRECAUTIONS 5 6. TECHNICAL HINTS 5 7. REAGENT SUPPLIED 6 8. MATERIAL REQUIRED BUT NOT SUPPLIED 6 9. PREPARATION OF REAGENTS 7 10. PREPARATION OF SAMPLES 9 11. ASSAY PROCEDURE 10 12. CALCULATIONS 12 13. PERFORMANCE CHARACTERISTICS 13 14. DEFINITION OF THE STANDARD 16 15. METHOD COMPARISON 16 16. TROUBLESHOOTING AND FAQS 17 17. REFERENCES 18 18. EXPLANATION OF SYMBOLS 20
This kit is manufactured by: BioVendor – Laboratorní medicína a.s.
Use only the current version of Product Data Sheet enclosed with the kit!
Page 2 of 24 ENG.006.A
1. INTENDED USE
The RD192090100R Human S100B ELISA is a sandwich enzyme immunoassay for the quantitative measurement of human S100B.
Features
• It is intended for research use only • The total assay time is less than 4.5 hours • The kit measures S100B protein in serum and cerebrospinal fluid samples • Assay format is 96 wells • Quality Controls are human serum based. Animal serum is used for Master Standard and Dilution Buffer preparations • Standard is native protein based • Components of the kit are provided ready to use, concentrated or lyophilized
2. STORAGE, EXPIRATION
Store the complete kit at 2-8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
For stability of opened reagents see Chapter 9.
Page 3 of 24 ENG.006.A
3. INTRODUCTION
S-100B is a member of highly homologous Ca2+ binding proteins family that possess two EF-hand motifs. The family of S100 proteins consists of 19 members. Most S100 proteins exist as dimers (frequently homodimers) within cells. Exclusively expressed in vertebrates, S100 is implicated in various intracellular and extracellular regulatory activities. Studies indicate that S100 proteins are involved in the inhibition of protein phosphorylation, inhibition of cytoskeletal constituent assembly, regulation of Ca2+ homeostasis, stimulation of enzyme activities, and interaction with transcription factors. S100B is abundant in the nervous system where it is predominantly expressed in astrocytes, oligodendrocytes and Schwann cells. When secreted by astrocytes, S100B has neurotrophic effects during development and nerve regeneration at physiologic (nanomolar) concentrations. However, high (micromolar) concentrations of S100B have shown to be neurotoxic, participating in the physiology of neurodegenerative disorders. The clinical values have been demonstrated in stroke, cerebral complications associated with cardiac arrest and in patients with severe as well as minor head injuries. Patients with progressive melanoma disease also show elevated serum concentrations of S100B.
Areas of investigation: Neural tissue damage Acute myocardial infarction Oncology
4. TEST PRINCIPLE
In the BioVendor Human S100B ELISA, standards, quality controls and samples are incubated in microplate wells pre-coated with monoclonal anti-human S100B antibody. After 120 minutes incubation and washing, biotin labelled monoclonal anti-human S100B antibody is added to the wells and incubated for 60 minutes with captured S100B. After another washing, Streptavidin-HRP Conjugate is added. After 30 minutes incubation and the last washing step, the remaining conjugate is allowed to react with the Substrate Solution (TMB). The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured. The absorbance is proportional to the concentration of S100B. A standard curve is constructed by plotting absorbance values against concentrations of Standards, and concentrations of unknown samples are determined using this standard curve.
Page 4 of 24 ENG.006.A
5. PRECAUTIONS
• For professional use only • Wear gloves and laboratory coats when handling immunodiagnostic materials • Do not drink, eat or smoke in the areas where immunodiagnostic materials are being handled • This kit contains components of human origin. These materials were found non-reactive for HBsAg, HCV antibody and for HIV 1/2 antigen and antibody. However, these materials should be handled as potentially infectious, as no test can guarantee the complete absence of infectious agents • This kit contains components of animal origin. These materials should be handled as potentially infectious • Avoid contact with the acidic Stop Solution and Substrate Solution, which contains hydrogen peroxide and tetramethylbenzidine (TMB). Wear gloves and eye and clothing protection when handling these reagents. Stop and/or Substrate Solutions may cause skin/eyes irritation. In case of contact with the Stop Solution and the Substrate Solution wash skin/eyes thoroughly with water and seek medical attention, when necessary • The materials must not be pipetted by mouth
6. TECHNICAL HINTS
• Reagents with different lot numbers should not be mixed • Use thoroughly clean glassware • Use deionized (distilled) water, stored in clean containers • Avoid any contamination among samples and reagents. For this purpose, disposable tips should be used for each sample and reagent • Substrate Solution should remain colourless until added to the plate. Keep Substrate Solution protected from light • Stop Solution should remain colourless until added to the plate. The colour developed in the wells will turn from blue to yellow immediately after the addition of the Stop Solution. Wells that are green in colour indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution • Dispose of consumable materials and unused contents in accordance with applicable national regulatory requirements
Page 5 of 24 ENG.006.A
7. REAGENT SUPPLIED
Kit Components State Quantity Antibody Coated Microtiter Strips ready to use 96 wells Biotin Labelled Antibody Conc. (100x) concentrated 0.13 ml Streptavidin-HRP Conjugate ready to use 13 ml Master Standard lyophilized 2 vial Quality Control HIGH lyophilized 1 vial Quality Control LOW lyophilized 1 vial Biotin-Ab Diluent ready to use 13 ml Dilution Buffer ready to use 20 ml Wash Solution Conc. (10x) concentrated 100 ml Substrate Solution ready to use 13 ml Stop Solution ready to use 13 ml Product Data Sheet + Certificate of Analysis - 1 pc
8. MATERIAL REQUIRED BUT NOT SUPPLIED
• Deionized (distilled) water • Test tubes for diluting samples • Glassware (graduated cylinder and bottle) for Wash Solution • Precision pipettes to deliver 10-1000 l with disposable tips • Multichannel pipette to deliver 100 l with disposable tips • Absorbent material (e.g. paper towels) for blotting the microtitrate plate after washing • Vortex mixer • Orbital microplate shaker capable of approximately 300 rpm • Microplate washer (optional). [Manual washing is possible but not preferable.] • Microplate reader with 450 10 nm filter, preferably with reference wavelength 630 nm (alternatively another one from the interval 550 - 650 nm) • Software package facilitating data generation and analysis (optional)
Page 6 of 24 ENG.006.A
9. PREPARATION OF REAGENTS
All reagents need to be brought to room temperature prior to use
Always prepare only the appropriate quantity of reagents for your test
Do not use components after the expiration date marked on their label
• Assay reagents supplied ready to use:
Antibody Coated Microtiter Strips Stability and storage: Return the unused strips to the provided aluminium zip-sealed bag with desiccant and seal carefully. Remaining Microtiter Strips are stable 3 months stored at 2-8°C and protected from the moisture.
Streptavidin-HRP Conjugate Biotin-Ab Diluent Dilution Buffer Substrate Solution Stop Solution Stability and storage: Opened reagents are stable 3 months when stored at 2-8°C.
• Assay reagents supplied concentrated or lyophilized:
Human S100B Master Standard Refer to the Certificate of Analysis for current volume of Dilution Buffer needed for reconstitution of standard!!! Reconstitute the lyophilized Master Standard according to the Certificate of Analysis to prepare standard stock solution just prior to the assay. Let it dissolve for 25-30 minutes with occasional gentle shaking (not to foam). The resulting concentration of the human S100B in the stock solution is 1600 pg/ml.
Page 7 of 24 ENG.006.A
Prepare set of standards using Dilution Buffer as follows:
Volume of Standard Dilution Buffer Concentration Stock - 1600 pg/ml 100 l of stock 400 l 320 pg/ml 250 l of 320 pg/ml 250 l 160 pg/ml 250 l of 160 pg/ml 250 l 80 pg/ml 250 l of 80 pg/ml 250 l 40 pg/ml 250 l of 40 pg/ml 250 l 20 pg/ml 250 l of 20 pg/ml 250 l 10 pg/ml
Mix thoroughly but gently (not to foam) after each dilution step. Prepared Standards are ready to use, do not dilute them. Stability and storage: Do not store the reconstituted Master Standard and/or diluted standard solutions.
Quality Controls HIGH, LOW Refer to the Certificate of Analysis for current volume of distilled water needed for reconstitution and for current Quality Control concentration!!! Reconstitute each Quality Control (HIGH and LOW) with distilled water just prior to the assay. Let it dissolve for 25-30 minutes with occasional gentle shaking (not to foam). Dilute Quality Controls prior to the assay 4x with Dilution Buffer, e.g. 40 l of Quality Control + 120 l of Dilution Buffer for singlets, or preferably 60 l of Quality Control + 180 l of Dilution Buffer for duplicates. Stability and storage: The reconstituted Quality Controls must be used immediately or aliquoted and frozen at -20°C for 3 months. Avoid repeated freeze/thaw cycles. Do not store the diluted Quality Controls. Note: Concentration of analyte in Quality Controls need not be anyhow associated with normal and/or pathological concentrations in serum or another body fluid. Quality Controls serve just for control that the kit works in accordance with PDS and CoA and that ELISA test was carried out properly.
Biotin Labelled Antibody Conc. (100x) Prepare the working Biotin Labelled Antibody solution by adding 1 part of Biotin Labelled Antibody Conc. (100x) to 99 parts of Biotin-Ab Diluent. Example (for 1 strip, i.e. 8 wells): 10 l of Biotin Labelled Antibody Conc. (100x) + 990 l Biotin-Ab Diluent. Stability and storage: Opened Biotin Labelled Antibody Conc. (100x) is stable 3 months when stored at 2-8°C. Do not store diluted Biotin Labelled Antibody solution.
Page 8 of 24 ENG.006.A
Wash Solution Conc. (10x) Dilute Wash Solution Conc. (10x) ten-fold in distilled water to prepare a 1x working solution. Example: 100 ml of Wash Solution Conc. (10x) + 900 ml of distilled water for use of all 96-wells. Stability and storage: The diluted Wash Solution is stable 1 month when stored at 2-8°C. Opened Wash Solution Conc. (10x) is stable 3 months when stored at 2-8°C.
10. PREPARATION OF SAMPLES
The kit measures S100B in serum and cerebrospinal fluid (CSF) samples. EDTA plasma and citrate plasma are not suitable kinds of samples because of unfavourable interactions between sample and Dilution Buffer components. No similar interaction has been observed with heparin plasma samples therefore it can be assumed that heparin plasma samples may be used in this ELISA. However heparin plasma samples could not be validated with this ELISA because suitable samples paired with serum samples from the same individuals were not available.
Samples should be assayed immediately after collection or should be stored at -20°C. Mix thawed samples thoroughly just prior to the assay and avoid repeated freeze/thaw cycles, which may cause erroneous results. Avoid using hemolyzed or lipemic samples.
An appropriate sample dilution should be assessed by the researcher in advance to batch measurement.
Recommended starting dilution for serum and CSF samples is 4x. Dilute samples 4x with Dilution Buffer just prior to the assay, e.g. 40 l of sample + 120 l of Dilution Buffer for singlets, or preferably 60 l of sample + 180 l of Dilution Buffer for duplicates. Mix thoroughly but gently (not to foam). Vortex is recommended. Stability and storage: Samples should be stored at -20°, or preferably at -70°C for long-term storage. Avoid repeated freeze/ thaw cycles. Do not store the diluted samples.
See Chapter 13 for stability of cerebrospinal fluid sample when stored at 2-8°C and effect of freezing/thawing on the concentration of S100B protein.
Note: It is recommended to use a precision pipette and a careful technique to perform the dilution in order to get precise results.
Ask for more detailed information at [email protected] if assaying heparin plasma samples or other kinds of samples.
Page 9 of 24 ENG.006.A
11. ASSAY PROCEDURE
1. Pipet 100 l of diluted Standards, Quality Controls, Dilution Buffer (=Blank) and samples, preferably in duplicates, into the appropriate wells. See Figure 1 for example of work sheet. 2. Incubate the plate at room temperature (ca. 25°C) for 120 minutes, shaking at ca. 300 rpm on an orbital microplate shaker. 3. Wash the wells 5-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel. 4. Add 100 l of Biotin Labelled Antibody solution into each well. 5. Incubate the plate at room temperature (ca. 25°C) for 60 minutes, shaking at ca. 300 rpm on an orbital microplate shaker. 6. Wash the wells 5-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel. 7. Add 100 l of Streptavidin-HRP Conjugate into each well. 8. Incubate the plate at room temperature (ca. 25°C) for 30 minutes, shaking at ca. 300 rpm on an orbital microplate shaker. 9. Wash the wells 5-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel. 10. Add 100 l of Substrate Solution into each well. Avoid exposing the microtiter plate to direct sunlight. Covering the plate with e.g. aluminium foil is recommended. 11. Incubate the plate for 15 - 30 minutes at room temperature. Longer incubation time (up to 30 minutes) is recommended if the colour development is slow. Do not shake the plate during the incubation. 12. Stop the colour development by adding 100 l of Stop Solution. 13. Determine the absorbance of each well using a microplate reader set to 450 nm, preferably with the reference wavelength set to 630 nm (acceptable range: 550 - 650 nm). Subtract readings at 630 nm (550 - 650 nm) from the readings at 450 nm. The absorbance should be read within 5 minutes following step 12.
Note 1: If some samples and standard/s have absorbances above the upper limit of your microplate reader, perform a second reading at 405 nm. A new standard curve, constructed using the values measured at 405 nm, is used to determine S100B concentration of off-scale standards and samples. The readings at 405 nm should not replace the readings for samples that were “in range” at 450 nm.
Note 2: Manual washing 5-times: Aspirate wells and pipet 0.35 ml Wash Solution into each well. Aspirate wells and repeat 4-times. After final wash, invert and tap the plate strongly against paper towel. Make certain that Wash Solution has been removed entirely.
Page 10 of 24 ENG.006.A
strip 1+2 strip 3+4 strip 5+6 strip 7+8 strip 9+10 strip 11+12 A Standard 320 Blank Sample 8 Sample 16 Sample 24 Sample 32 B Standard 160 Sample 1 Sample 9 Sample 17 Sample 25 Sample 33 C Standard 80 Sample 2 Sample 10 Sample 18 Sample 26 Sample 34 D Standard 40 Sample 3 Sample 11 Sample 19 Sample 27 Sample 35 E Standard 20 Sample 4 Sample 12 Sample 20 Sample 28 Sample 36 F Standard 10 Sample 5 Sample 13 Sample 21 Sample 29 Sample 37 G QC HIGH Sample 6 Sample 14 Sample 22 Sample 30 Sample 38 H QC LOW Sample 7 Sample 15 Sample 23 Sample 31 Sample 39
Figure 1: Example of a work sheet.
Page 11 of 24 ENG.006.A
12. CALCULATIONS
Most microplate readers perform automatic calculations of analyte concentration. The standard curve is constructed by plotting the mean absorbance (Y) of Standards against the known concentration (X) of Standards in logarithmic scale, using the four-parameter algorithm. Results are reported as concentration of S100B pg/ml in samples.
Alternatively, the logit log function can be used to linearize the standard curve, i.e. logit of the mean absorbance (Y) is plotted against log of the known concentration (X) of Standards.
The measured concentration of S100B in samples and in Quality Controls calculated from the standard curve must be multiplied by their respective dilution factor, because samples and controls have been diluted prior to the assay, e.g. 75.5 pg/ml (from standard curve) x 4 (dilution factor) = 302 pg/ml.
Figure 2: Typical Standard curve for Human S100B ELISA.
Page 12 of 24 ENG.006.A
13. PERFORMANCE CHARACTERISTICS
Typical analytical data of BioVendor Human S100B ELISA are presented in this chapter
• Sensitivity The measurement range of the assay is 10 - 320 pg/ml (final concentration in a well after dilution).
• Limit of assay Samples with absorbances exceeding the absorbance of the highest standard should be measured again with higher dilution. The final concentration of samples calculated from the standard curve must be multiplied by the respective dilution factor.
• Specificity The antibodies used in this ELISA are specific for human S100B with no detectable crossreactivities to human S100A1, S100A4, S100A5, S100A8, S100A9, S100A10, S100A11, S100A14, S100A15, S100A16, S100G.
High S100B concentration was detected in diluted (1 000x – 2 000x) mouse brain homogenate samples using this ELISA.
Sera of several mammalian species were measured in the assay. Positive reactivity has been found in these animal sera: bovine, cat, goat, hamster, rhesus monkey, rabbit and rat. For details please contact us at [email protected].
S100B protein amino acid sequence is highly conserved (e.g. there is only 1 amino acid difference between mouse and human S100B protein sequences), therefore cross reactivity with some animal S100B proteins may be expected. On the other hand, very low or zero S100B levels found in animal serum samples can reflect in some cases only absence of S100B in those particular serum samples from animals with the uninjured brain.
Page 13 of 24 ENG.006.A
Presented results are multiplied by respective dilution factor
• Precision Intra-assay (Within-Run) (n=8) Sample Mean SD CV (pg/ml) (pg/ml) (%) 1 259.3 5.4 2.1 2 403.4 7.8 1.9
Inter-assay (Run-to-Run) (n=4) Sample Mean SD CV (pg/ml) (pg/ml) (%) 1 105.0 7.5 7.1 2 341.3 16.0 4.7
• Spiking Recovery Serum and cerebrospinal fluid (CSF) samples were spiked with different amounts of human S100B antigen and assayed. Sample Observed Expected Recovery O/E (pg/ml) (pg/ml) (%) Serum sample 568.6 - - 863.8 888.6 97.2 1168.9 1208.6 96.7 1760.8 1848.6 95.3 CSF sample 268.2 - - 424.4 368.2 115.3 478.1 468.2 102.1 706.4 668.2 105.7
• Linearity Serum and CSF samples were serially diluted with Dilution Buffer and assayed. Sample Dilution Observed Expected Recovery (pg/ml) (pg/ml) O/E (%) Serum - 420.5 - - sample 2x 212.3 210.3 101.0 4x 111.2 105.1 105.7 8x 58.6 52.6 111.4 CSF - 827.3 - - sample 2x 481.3 413.7 116.4 4x 237.1 206.8 114.6 8x 124.7 103.4 120.6
Page 14 of 24 ENG.006.A
• Stability of samples stored at 2-8°C Samples should be stored at –20°C. However, no decline in concentration of S100B was observed in cerebrospinal fluid samples after 14 days when stored at 2-8°C. To avoid microbial contamination, samples were treated with -aminocaproic acid and sodium azide, resulting in the final concentration of 0.03% and 0.1%, respectively.
Cerebrospinal fluid Sample Incubation Temp, Period (pg/ml) -20°C 148.3 2-8°C, 1 day 142.9 1 2-8°C, 7 days 141.7 2-8°C, 14 days 149.2 -20°C 190.3 2-8°C, 1 day 202.5 2 2-8°C, 7 days 196.4 2-8°C, 14 days 188.2 -20°C 183.1 2-8°C, 1 day 183.1 3 2-8°C, 7 days 168.3 2-8°C, 14 days 172.8
• Effect of Freezing/Thawing Concentration of human S100B in cerebrospinal fluid samples declined more than 30% after repeated (3x) freeze/thaw cycles. It is strongly recommended to avoid repeated freezing/thawing of the samples.
Cerebrospinal fluid Sample Number of f/t cycles (pg/ml) 1x 221.3 1 3x 132.1 5x 93.1 1x 218.8 2 3x 191.5 5x 174.3 1x 304.8 3 3x 203.7 5x 191.0
Page 15 of 24 ENG.006.A
• Comparison of serum and CSF samples Serum samples and cerebrospinal fluids were taken from 8 patients with head injury or brain disorder and measured in the assay, results shown below:
Volunteer No. Serum Cerebrospinal fluid (pg/ml) (pg/ml) 1 95.7 394 2 52.3 2 194 3 31.8 485 4 42.6 479 5 0 237 6 0 890 7 0 575 8 0 893
• Reference range It is recommended that each laboratory include its own panel of control samples in the assay. Each laboratory should establish its own normal and pathological reference ranges for human S100B levels with the assay.
14. DEFINITION OF THE STANDARD
A S100B ( homodimer) protein purified from human brain tissue is used as the standard in this assay. S100B is a 21 kDa protein.
15. METHOD COMPARISON
The Biovendor Human S100B ELISA has not been compared to other commercial immunoassays.
Page 16 of 24 ENG.006.A
16. TROUBLESHOOTING AND FAQS
Weak signal in all wells Possible explanations: • Omission of a reagent or a step • Improper preparation or storage of a reagent • Assay performed before reagents were allowed to come to room temperature • Improper wavelength when reading absorbance
High signal and background in all wells Possible explanations: • Improper or inadequate washing • Overdeveloping; incubation time with Substrate Solution should be decreased before addition of Stop Solution • Incubation temperature over 30°C
High coefficient of variation (CV) Possible explanations: • Improper or inadequate washing • Improper mixing Standards, Quality Controls or samples
Page 17 of 24 ENG.006.A
17. REFERENCES
References to S100B:
• Zimmer DB et al.: The S100 Protein Family: History, Function, and Expression. Brain Research Bulletin. 37(4):417-429 (1995) • Kärnell R et al.: S100B Protein, 5-S-Cysteinyldopa and 6-Hydroxy-5-Methoxyindole-2- Carboxylic Acid as Biochemical Markers for Survival Prognosis in Patients with Malignant Melanoma. Melanoma Research 7(5):393-399 (1997) • Jönsson H et al.: S100β After Coronary Artery Surgery: Release Pattern, Source of Contamination, and Relation to Neuropsychological Outcome. Ann Thorac Surg. 68(6): 2202-2208 (1999) • Hauschild A et al.: S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma. Oncology 56(4):338-344 (1999) • Donato R: S100: a Multigenic Family of Calcium-Modulated Proteins of the EF-Hand Type with Intracellular and Extracellular Functional Roles. Int J Biochem Cell Biol. 33(7): 637-68 (2001) • Reynolds MA et al.: Early Biomarkers of Stroke. Clinical Chemistry 49(10):1733-1739 (2003) • Johnsson P et al.: Increased S100B in Blood After Cardiac Surgery Is a Powerful Predictor of Late Mortality. Ann Thorac Surg 75(1):162-168 (2003) • Beems T et al.: Serum- and CSF-concentrations of Brain Specific Proteins in Hydrocephalus. Acta Neurochir 145(1):37-43 (2003) • Gazzolo D et al.: S100B protein in urine of preterm newborns with ominous outcome. Pediatr Res. 58(6):1170-4 (2005) • Fernandez-Fernandez MR et al.: Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci USA. 102(13):4735-40 (2005) • Delgado P et al.: Plasma S100B level after acute spontaneous intracerebral hemorrhage. Stroke. 37(11):2837-9 (2006) • Ralay Ranaivo H et al.: Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci. 26(2):662-70 (2006) • Sanchez-Juan P et al.: CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 67(4):637-43 (2006) • Steiner J et al.: Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry. 77(11):1284-7(2006) • Steiner J et al.: Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci. 8:2 (2007) • Berger RP et al.: Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma. 24(12):1793-801 (2007)
Page 18 of 24 ENG.006.A
• Foerch C et al.: Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke. 38(9):2491-5 (2007)
References to this product:
• Friel LA et al.: The calcium binding protein, S100B, is increased in the amniotic fluid of women with intra-amniotic infection/inflammation and preterm labor with intact or ruptured membranes. J Perinat Med. 35(5):385-93 (2007) • Hamed SA et al.: Oxidative stress and S-100B protein in children with bacterial meningitis. BMC Neurol. 9:51 (2009) • Misu T et al.: Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 80(5): 575-7 (2009) • Celikbilek A et al.: The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis. Int J Inflam. 2014:986525 (2014) • Brouns R et al.: Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients. Clin Chem. 56(3):451-8 (2010)
For more references on this product see our Web Pages at www.biovendor.com
Page 19 of 24 ENG.006.A
18. EXPLANATION OF SYMBOLS
Catalogue number
Content
Lot number
Attention, see instructions for use
Potential biological hazard
Expiry date
Storage conditions
Name and registered office of the manufacturer
Page 20 of 24 ENG.006.A
Assay Procedure Summary
Antibody Coated Microtiter Strips
Reconstitute QCs and Master Standard and prepare set of Standards
Dilute samples 4x Dilute QCs 4x Add Standards, QCs and samples 100 l
Incubate at RT for 120 min / 300rpm Prepare Wash Solution
Wash 5x Prepare Biotin Labelled Antibody solution Add Biotin Labelled Antibody solution 100 l
Incubate at RT for 60 min / 300rpm
Wash 5x
Add Streptavidin-HRP Conjugate 100 l Incubate at RT for 30 min / 300rpm
Wash 5x
Add Substrate Solution 100 l
Incubate at RT for 15 - 30 min
Add Stop Solution 100 l
Read absorbance and calculate results
Page 21 of 24 ENG.006.A
12
11
10
9
8
7
6
5
4
3
2
1
F
E
A B C D H G
Page 22 of 24 ENG.006.A
NOTES
Page 23 of 24 ENG.006.A
Page 24 of 24 ENG.006.A